Relationship between cerebral small vessel disease and proteinopathies in the medial temporal lobe

Valentina Perosa1, Jan Oltmer2, Francesco Bax3,4

  • 1J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Cambridge Str. 175, Suite 300, Boston, MA, 02114, USA. VPEROSA@mgh.harvard.edu.

Insights

Cerebral small vessel disease (CSVD) and Alzheimer's Disease (AD) proteinopathies coexist in the medial temporal lobe. Cerebral amyloid angiopathy (CAA) is linked to AD proteinopathies, while arteriolosclerosis may impair brain clearance.

Area of Science:

  • Neuropathology
  • Neurodegenerative Diseases
  • Cerebrovascular Diseases

Background:

  • The medial temporal lobe (MTL) is crucial for cognition and Alzheimer's Disease (AD) pathogenesis.
  • Cerebral small vessel disease (CSVD) independently impacts cognition and may interact with AD.
  • The interplay between CSVD subtypes and AD-related proteinopathies in the MTL is not well understood.

Purpose of the Study:

  • To quantitatively assess the severity of CSVD and its association with AD proteinopathies (tau-tangles, amyloid-β-plaques, pTDP-43) in the MTL.
  • To investigate the relationship between CSVD and enlarged perivascular spaces (PVS) as a marker of impaired clearance.

Main Methods:

  • AI and manual analysis of digitized MTL histology from 152 autopsy cases.
  • Quantification of cerebral amyloid angiopathy (CAA) and arteriolosclerosis.
  • Assessment of tau-tangles, amyloid-β-plaques, and pTDP-43 burden.
  • Linear-mixed-effects models to analyze associations between CSVD, proteinopathies, and PVS enlargement.

Main Results:

  • CAA burden correlated with Braak stage and was associated with amyloid-β-plaques and tau-tangles, independent of Braak stage.
  • Arteriolosclerosis severity did not directly associate with parenchymal proteinopathies.
  • Arteriolosclerosis and its interaction with CAA were linked to PVS enlargement, suggesting impaired perivascular clearance.

Conclusions:

  • Cerebral amyloid angiopathy (CAA), a form of CSVD, is directly implicated in the pathophysiology of MTL proteinopathies.
  • Arteriolosclerosis, another CSVD form, may contribute to perivascular clearance dysfunction in the MTL.
  • These findings highlight distinct roles for CSVD subtypes in AD pathogenesis and brain clearance mechanisms.